What do systematic reviews say?

4 questions · 4 findings · 2 reviews · Hypertension

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 50%Low 1 · 25%Moderate 1 · 25%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Phentermine/topiramate vs placebo · All adverse events
  Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
  RR 1.13 [1.08, 1.2]
  1 study · 1305 participants
  Low
Direct match · question page
- Orlistat vs placebo · All adverse events
  Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
  RR 1.13 [0.84, 1.54]
  2 studies · 1386 participants
  Very low
Direct match · question page
- Naltrexone/bupropion vs placebo · All adverse events
  Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
  RR 1.69 [1.58, 1.8]
  1 study · 8283 participants
  Moderate
Direct match · question page
- Evening vs morning dosing regimen · Overall adverse events
  Evening versus morning dosing regimen drug therapy for hypertension 2024 · Cochrane Headline outcomes only
  RR 0.89 [0.67, 1.2]
  7 studies · 1541 participants
  Very low

Phentermine/topiramate vs placebo

All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension

Phentermine/topiramate may leads to higher all adverse events compared with placebo (low certainty).

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
RR 1.13 [1.08, 1.2]
1 study · 1305 participants
Low

Naltrexone/bupropion vs placebo

All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension

Naltrexone/bupropion probably leads to higher all adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
RR 1.69 [1.58, 1.8]
1 study · 8283 participants
Moderate

Orlistat vs placebo

All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension

It is very uncertain whether orlistat changes all adverse events compared with placebo (very low certainty).

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
RR 1.13 [0.84, 1.54]
2 studies · 1386 participants
Very low

Evening vs morning dosing regimen

Overall adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater

It is very uncertain whether evening changes overall adverse events compared with morning dosing regimen (very low certainty).

1 finding from 1 review

Evening versus morning dosing regimen drug therapy for hypertension 2024 · Cochrane Headline outcomes only
RR 0.89 [0.67, 1.2]
7 studies · 1541 participants
Very low